Hansa Biopharma announces Idefirix PAES late-breaking abstract selected for oral presentation in High-Impact Clinical Trials session at ASN Kidney Week
Lund, Sweden, October 20, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the European Post-Authorization Efficacy and Safety (PAES) study of Idefirix® (imlifidase) has been selected by the Committee for an oral abstract presentation in the High-Impact Clinical Trials session at ASN Kidney Week in Denver, US.
